Table 2.

Frequency of hypermethylation of KRT7, SLC15A3, and TACSTD2 by lesion and histologic grade and stage

KRT7, n (%)PSLC15A3, n (%)PTACSTD2, n (%)P
MUMUMU
PIN (19)10 (53)9 (47)1.007 (37)12 (63)0.0510 (0)19 (100)0.08
Prostate tumors (35)19 (54)16 (46)23 (66)12 (34)6 (17)29 (83)
Gleason ≤713 (72)5 (28)0.03712 (67)6 (33)1.002 (11)16 (89)0.39
Gleason ≥85 (31)11 (69)11 (69)5 (31)4 (25)12 (75)
Stage I-II9 (69)4 (31)0.299 (69)4 (31)1.001 (7.7)12 (92.3)0.38
Stage III-IV10 (45)12 (55)14 (64)8 (36)5 (23)17 (77)

NOTE: Fisher's exact test was used to analyze whether the hypermethylation of a given gene was related to tumor grade or stage. Results were declared statistically significant at the 5% significance level. M, number of patients with methylated gene. U, number of patients with unmethylated gene.